Clinical Trials Directory

Trials / Unknown

UnknownNCT03817671

The Clinical Outcome of Ultra-low Oxygen Tension on Post Thawed Human Blastocyst

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
168 (estimated)
Sponsor
Ganin Fertility Center · Academic / Other
Sex
All
Age
5 Days – 6 Days
Healthy volunteers
Not accepted

Summary

The clinical outcome of Ultra-low oxygen tension on post thawed human blastocyst

Detailed description

In vitro, Embryo development depends on several factors as temperature, pH, and oxygen in the surrounding environment of the embryo. Impaired culture conditions are highly correlated with poor embryo development. Oxygen is a powerful regulator of embryo function , as it is responsible for cell respiration, energy production and rapid cell growth . Increased levels of oxygen is associated with an increase in the levels of ROS , which leads to unfavorable culture conditions, as it might affect the stability of cell membrane, DNA, and protein function . In the female reproductive tract, oxygen concentration fluctuates between 2-8%, which is considered to be at its highest level in the fallopian tube, while the lowest level is in the uterus . Pre-implantation embryo crosses the uterotubal junction after the time of compaction on Day 3, where it is exposed to a shift in oxygen tension to 2%. This variation may have a role in the metabolic reactions of the embryo, and in its preparation for implantation process. Some studies suggested that culturing embryos with oxygen tension below 5% may have an embryological advantage mimicking nature. Embryological laboratories routinely use low Oxygen tension (5%). Our purpose is to investigate if ultra-low oxygen tension (2%) has an advantage over low oxygen tension (5%) for post thawed human embryo regarding clinical outcomes.

Conditions

Interventions

TypeNameDescription
OTHER5% O2Culturing embryos in 5% O2 just after thawing and till embryo transfer
OTHER2% O2Culturing embryos in 2% O2 just after thawing and till embryo transfer

Timeline

Start date
2018-11-20
Primary completion
2020-06-30
Completion
2020-06-30
First posted
2019-01-25
Last updated
2019-01-28

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03817671. Inclusion in this directory is not an endorsement.